ProMIS Neurosciences, Inc. (PMN) Cash Flow Statement

The wide variance in the OCF/NI ratio suggests that investors should disregard net income as a proxy for operational health. The persistent disconnect between accounting losses and cash depletion highlights the reliance on non-operating items, likely related to warrant valuations, which masks the underlying cash burn.

The trajectory of FCF outflows appears to be accelerating in recent periods, correlating with the advancement of clinical programs. This trend suggests that the company is entirely dependent on external capital markets to fund its research pipeline, as there is no evidence of a path toward FCF breakeven.

These swings in working capital suggest that the company's cash position is sensitive to the timing of vendor payments and clinical trial milestones. Investors should monitor these fluctuations closely, as they can temporarily mask or exacerbate the underlying cash burn rate during critical development phases.

The absence of capital return programs is expected for a firm at this stage, yet the lack of non-dilutive partnership capital suggests that management has not yet achieved the necessary clinical validation to attract external funding. This forces a reliance on equity markets, which may continue to dilute existing shareholders.